SavedAdd your journal

Journals / Klimik Dergisi / 2015 / Cilt: 28 - Sayı: 3

A Rare Side Effect Due to Tenofovir Disoproxil Fumarate: Pruritus

Tenofovir Disoproksil Fumarata Bağlı Nadir Bir Yan Etki: Kaşıntı

Neşe DEMİRTÜRK
Havva TÜNAY
Zerrin AŞCI
Pages
126–128
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Klimik Dergisi 2015; 28(3): 126-8

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tenofovir disoproxil fumarate (TDF) is a potent antiviral drug that has a high genetic barrier.
📊
Key Findings & Data:It is used in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B.
💡
Conclusion & Impact:Klimik Dergisi 2015; 28(3): 126-8
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Tenofovir disoproxil fumarate (TDF) is a potent antiviral drug that has a high genetic barrier. It is used in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B. Termination of the TDF therapy because of side effects is very rare. Pruritus is not taken into account as a reason of termination in the literature. A case of chronic hepatitis B whose treatment was terminated because of pruritus is presented. Klimik Dergisi 2015; 28(3): 126-8

Özet

Tenofovir disoproksil fumarat (TDF) insan immün yetmezlik virusu (HIV) infeksiyonu ve kronik hepatit B tedavisinde kullanılan yüksek genetik bariyerli potent bir antiviral ilaçtır. Yan etki nedeniyle TDF tedavisinin sonlandırılma yüzdesi çok düşüktür. Literatürde kaşıntı, tedavi sonlandırılma nedenleri arasında sayılmamıştır. Bu yazıda, TDF kullanımına bağlı kaşıntı nedeniyle tedavisi sonlandırılan bir kronik hepatit B olgusu sunulmuştur. Klimik Dergisi 2015; 28(3): 126-8

🔖

Cite This Article

DEMİRTÜRK, N., TÜNAY, H., AŞCI, Z. (2022). A Rare Side Effect Due to Tenofovir Disoproxil Fumarate: Pruritus. Klimik Dergisi, Cilt: 28 - Sayı: 3, 126–128. https://ajindex.com/articles/573611

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol- ogy. 2009; 50(3): 661-2. [CrossRef] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepa- tol. 2009; 50(2): 227-42. [CrossRef] Ahn SS, Chon YE, Kim BK, et al. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Clin Mol Hepatol. 2014; 20(3): 261-6. [CrossRef] Wong VW, Chan HL. Chronic hepatitis B: a treatment update. Se- min Liver Dis. 2013; 33(2): 122-9. [CrossRef] Akhan S, Aynıoğlu A, Çağatay A, et al. Kronik hepatit B virusu infeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu. Klimik Derg. 2014; 27(Suppl. 1): 2-18. [CrossRef] Verma R, Vasudevan B, Shankar S, Pragasam V, Suwal B, Venu- gopal R. First reported case of tenofovir-induced photoallergic reaction. Indian J Pharmacol. 2012; 44(5): 651-3. [CrossRef] Demirtürk N, Demirdal T. Yüksek genetik bariyerli antivirallerle tedavi edilen kronik hepatit B hastalarında gözlenen yan etkiler. Yeni Tıp Dergisi. 2011; 28(3): 146-9.
  2. Demir NA, Kölgelier S, Demir LS, et al. Naif kronik hepatit B hastalarının bir yıllık 245 mg/gün tenofovir disoproksil fumarat teda- vi sonuçlarının değerlendirilmesi. Nobel Medicus. 2013; 9(2): 57-62.
  3. Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treat- ment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2010; 8(10): 1079-92. [CrossRef] Kim HJ, Cho JY, Kim YJ, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide ana- logue failure in chronic hepatitis B patients. Korean J Intern Med. 2015; 30(1): 32-41. [CrossRef] Moss DM, Neary M, Owen A. The role of drug transporters in the kid- ney: lessons from tenofovir. Front Pharmacol. 2014; 5: 248. [CrossRef] Saeedi R, Jiang SY, Holmes DT, Kendler DL. Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. Calcif Tissue Int. 2014; 94(6): 665-8. [CrossRef] Abraham P, Ramamoorthy H, Isaac B. Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate- induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. J Biomed Sci. 2013; 2061. [CrossRef] Woolley IJ, Veitch AJ, Harangozo CS, Moyle M, Korman TM. Li- chenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient